{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-001508","form_type":"8-K","ticker":"SLSN","cik":"0000883107","company_name":"SOLESENCE, INC.","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.129256+00:00","generated_at":"2026-06-04T11:04:55.655604+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nanophase Q4/FY2023 revenue flat at $37.3M; net loss widens to $4.4M; secures $6M financing","bullets":["Q4 revenue $8.0M (vs $8.3M YoY); full-year revenue $37.3M flat; net loss $4.4M ($0.09/sh) vs $2.6M in 2022.","Solésence revenue grew 9% to $25.2M; Personal Care Ingredients fell 17% to $9.3M; Advanced Materials fell 9% to $2.8M.","Closed $6M financing package in March 2024 to support working capital and growth.","Litigation costs contributed $1.3M to operating loss; company expects lower costs and positive resolution ahead.","Management expects $35M in shipped and open POs so far in 2024, with more orders expected in Q2-Q3."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-001508","json":"https://secwatch.observer/filing/0001171843-24-001508.json","markdown":"https://secwatch.observer/filing/0001171843-24-001508.md","text":"https://secwatch.observer/filing/0001171843-24-001508.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/883107/000117184324001508/0001171843-24-001508-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/883107/000117184324001508/f8k_032024.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T11:04:55.655604+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5b12fc130629c3969f00978234a97a899f49b37d","claim":"SOLESENCE, INC. reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue $8 million, net income $2.1 million.","evidence_excerpt":"(PRESS RELEASE) --- EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Nanophase Reports Fourth Quarter and Year End 2023 Results, New Financing Package — Delivered $37.3 million in full year revenue — Closed on $6 million financing — Won 2024 Cosmetics and Toiletries Allē Award Finished Formula Prestige Category ROMEOVILLE, Ill., March 20, 2024 (GLOBE","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/883107/000117184324001508/0001171843-24-001508-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$8 million"},{"label":"Net income","value":"$2.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"5b12fc130629c3969f00978234a97a899f49b37d","claim":"SOLESENCE, INC. reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue $8 million, net income $2.1 million.","evidence_excerpt":"and operations management efforts,” added Cureton. 2023 Q4 Financial Information Fourth Quarter and Full Year 2023 Financial Highlights Revenue for the fourth quarter was $8 million, vs. $8.3 million for the same period in 2022. Revenue for the full year was $37.3 million, which was the same for 2022. Additional capital was secured with a $6 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/883107/000117184324001508/0001171843-24-001508-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$8 million"},{"label":"Net income","value":"$2.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}